KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 80 filers reported holding KINNATE BIOPHARMA INC in Q4 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $2,988,000 | -5.2% | 250,000 | 0.0% | 0.06% | -9.2% |
Q2 2022 | $3,153,000 | -71.6% | 250,000 | -74.6% | 0.06% | -73.8% |
Q1 2022 | $11,097,000 | -36.5% | 985,568 | 0.0% | 0.25% | -32.2% |
Q4 2021 | $17,464,000 | -26.2% | 985,568 | -4.2% | 0.37% | -20.8% |
Q3 2021 | $23,676,000 | -0.3% | 1,028,508 | +0.8% | 0.46% | +9.5% |
Q2 2021 | $23,746,000 | +120.9% | 1,020,000 | +195.7% | 0.42% | +86.7% |
Q1 2021 | $10,750,000 | -21.7% | 345,000 | 0.0% | 0.23% | -16.6% |
Q4 2020 | $13,724,000 | – | 345,000 | – | 0.27% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 9,671,643 | $225,156,000 | 30.44% |
Vida Ventures Advisors, LLC | 2,747,433 | $63,960,000 | 16.04% |
Foresite Capital Management V, LLC | 875,001 | $20,370,000 | 8.01% |
VR Adviser, LLC | 1,473,014 | $34,292,000 | 4.16% |
Logos Global Management LP | 1,329,602 | $30,953,000 | 2.60% |
RA Capital Management | 3,593,052 | $83,646,000 | 1.34% |
Orbimed Advisors | 3,847,929 | $89,580,000 | 0.91% |
Boxer Capital, LLC | 1,065,939 | $24,815,000 | 0.88% |
HARVARD MANAGEMENT CO INC | 498,001 | $11,593,000 | 0.67% |
HighVista Strategies LLC | 33,391 | $777,000 | 0.55% |